Marinus Pharmaceuticals Inc. (61Y)

Overview

Marinus Pharmaceuticals, Inc. is a specialized pharmaceutical company concentrating on the development and commercialization of novel therapeutic offerings for individuals afflicted with rare genetic epilepsies and various seizure disorders. Established in 2003 and based in Radnor, Pennsylvania, the company's mission is to address the unmet medical needs of patients with severe neurological conditions. Marinus Pharmaceuticals has established strategic agreements with notable entities such as Purdue Neuroscience Company, CyDex Pharmaceuticals, Inc., Orion Corporation, and Tenacia Biotechnology (Shanghai) Co., Ltd., aiming to enhance its product development and commercialization capabilities.

Products and Services

- ZTALMY (ganaxolone) Oral Suspension:

This product is a flagship offering from Marinus Pharmaceuticals, specifically designed for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare genetic condition. It is approved for use in both adults and pediatric populations, and is available for administration in various settings, from acute and chronic care facilities to patient self-administration at home. The mechanism of action of ZTALMY involves modulation of GABAA receptors, which play a key role in controlling neuronal excitability and are known targets for their anti-seizure, antidepressant, and anxiolytic effects.

- Ganaxolone Development for Additional Genetic Epilepsy Disorders:

Beyond ZTALMY, Marinus Pharmaceuticals is advancing ganaxolone for the treatment of other genetic epilepsy disorders. These include PCDH19-related epilepsy and tuberous sclerosis complex (TSC), both of which represent areas of significant unmet medical need. The company's efforts to extend the benefits of ganaxolone to these conditions underscores its commitment to leveraging its proprietary technology for broadening its impact on people living with hard-to-treat seizure disorders.